IP Library › Granted Patent US 12,703,738
Granted Patent B2
US 12,703,738 · App. 17/530,542 · Granted Aug 11, 2026

Antibody constant region variant

Inventors: Tomoyuki Igawa (Shizuoka, JP); Taichi Kuramochi (Shizuoka, JP); Atsuhiko Maeda (Shizuoka, JP); Hirotake Shiraiwa (Shizuoka, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha
C07K16/00C07K16/2866C07K16/2875C07K2317/515C07K2317/52C07K2317/522C07K2317/524C07K2317/526C07K2317/528C07K2317/53C07K2317/71C07K2317/72C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,703,738
App. No.
17/530,542
Granted
Aug 11, 2026
Kind
B2
Abstract

Disclosed are IgG2 constant regions and human κ chain constant regions with altered amino acid sequences, antibodies comprising these constant regions, and pharmaceutical compositions comprising the antibodies.

Claims (27)

1 . An antibody constant region comprising the amino acid sequence of SEQ ID NO: 24 with at least the following substitutions and optional deletions:

Ser is substituted for Cys at position 14, which corresponds to EU numbering position 131;

Lys is substituted for Arg at position 16, which corresponds to EU numbering position 133;

Ser is substituted for Cys at position 103, which corresponds to EU numbering position 220;

Gly is substituted for Glu at position 20, which corresponds to EU numbering position 137;

Gly is substituted for Ser at position 21, which corresponds to EU numbering position 138;

Gln is substituted for His at position 147, which corresponds to EU numbering position 268;

Gln is substituted for Arg at position 234, which corresponds to EU numbering position 355; and

Glu is substituted for Gln at position 298, which corresponds to EU numbering position 419,

wherein Gly at position 325 and Lys at position 326 of SEQ ID NO: 24, corresponding to EU numbering positions 446 and 447, respectively, are optionally deleted.

2 . An antibody constant region comprising the amino acid sequence of SEQ ID NO: 24 with at least the following substitutions and optional deletions:

Ser is substituted for Cys at position 14, which corresponds to EU numbering position 131;

Lys is substituted for Arg at position 16, which corresponds to EU numbering position 133;

Ser is substituted for Cys at position 103, which corresponds to EU numbering position 220;

Gly is substituted for Glu at position 20, which corresponds to EU numbering position 137;

Gly is substituted for Ser at position 21, which corresponds to EU numbering position 138;

Gln is substituted for His at position 147, which corresponds to EU numbering position 268;

Gln is substituted for Arg at position 234, which corresponds to EU numbering position 355;

Glu is substituted for Gln at position 298, which corresponds to EU numbering position 419;

Ser is substituted for Ala at position 209, which corresponds to EU numbering position 330;

Ser is substituted for Pro at position 210, which corresponds to EU numbering position 331; and

Ala is substituted for Thr at position 218, which corresponds to EU numbering position 339,

wherein Gly at position 325 and Lys at position 326 of SEQ ID NO: 24, corresponding to EU numbering positions 446 and 447, respectively, are optionally deleted.

3 . The antibody constant region of claim 1 , wherein Gly at position 325 and Lys at position 326 of SEQ ID NO: 24 are deleted.

4 . The antibody constant region of claim 2 , wherein Gly at position 325 and Lys at position 326 of SEQ ID NO: 24 are deleted.

5 . An antibody comprising the constant region of any one of claims 1, 2, 3, and 4 .

6 . A pharmaceutical composition comprising the antibody of claim 5 .